Clinical Trial Update: Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients [EARLY_Phase 1]

View source ↗

Summary

Early-phase clinical trial investigating the effects of a PARP inhibitor on the tumor microenvironment in high-risk endometrial cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• PARP inhibitor (unspecified)

Snippet

Sponsor: The University of Hong Kong | Conditions: Endometrial Cancer | EARLY_Phase 1 | Status: COMPLETED